» Articles » PMID: 25999740

Primary Paraesophageal Ewing's Sarcoma: an Uncommon Case Report and Literature Review

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2015 May 23
PMID 25999740
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Ewing's sarcoma is a rare and highly aggressive cancer most frequently arising in people under 20 years of age. We report an uncommon case of primary paraesophageal Ewing's sarcoma in a 25-year-old male harboring the infrequent EWSR1/ERG fusion transcript with multiple splice variants coexisting in the same tumor. The patient was totally refractory to chemotherapy and died 17 months after diagnosis. We underscore the need for better understanding of the molecular pathogenesis of the disease and improved systemic therapy options.

Citing Articles

Ewing Sarcoma and Primitive Neuroectodermal Tumor of the Thoracic Esophagus: Case Report and Comprehensive Literature Review.

Li J, Sun P, Ma L, Min X, Ye B, Zhang Y Case Rep Oncol. 2022; 15(1):267-276.

PMID: 35529299 PMC: 9035948. DOI: 10.1159/000522152.


Extra Skeletal Ewing's Sarcoma: a Case Report.

Mir Mohmmad Sadeghi H, Mashhadi Abbas F, Taghavi N, Baharnoori N J Dent (Shiraz). 2020; 21(1):73-76.

PMID: 32158788 PMC: 7036358. DOI: 10.30476/DENTJODS.2019.44908.


Defining a Characteristic Gene Expression Set Responsible for Cancer Stem Cell-Like Features in a Sub-Population of Ewing Sarcoma Cells CADO-ES1.

Hotfilder M, Mallela N, Seggewiss J, Dirksen U, Korsching E Int J Mol Sci. 2018; 19(12).

PMID: 30563222 PMC: 6321634. DOI: 10.3390/ijms19123908.


MiR-107 suppresses cell proliferation and tube formation of Ewing sarcoma cells partly by targeting HIF-1β.

Chen J, Zhou X, Xiao Q, Wang T, Shao G, Li Y Hum Cell. 2017; 31(1):42-49.

PMID: 29075999 DOI: 10.1007/s13577-017-0183-9.

References
1.
Patocs B, Nemeth K, Garami M, Arato G, Kovalszky I, Szendroi M . Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors. Cell Oncol (Dordr). 2013; 36(3):191-200. DOI: 10.1007/s13402-013-0126-8. View

2.
Brenner J, Feng F, Han S, Patel S, Goyal S, Bou-Maroun L . PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012; 72(7):1608-13. PMC: 3319786. DOI: 10.1158/0008-5472.CAN-11-3648. View

3.
Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Smith T . Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?. J Clin Oncol. 1996; 14(4):1245-51. DOI: 10.1200/JCO.1996.14.4.1245. View

4.
Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N . Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011; 17(18):6052-60. PMC: 3176947. DOI: 10.1158/1078-0432.CCR-10-2979. View

5.
Leavey P, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J . Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2008; 51(3):334-8. PMC: 2728357. DOI: 10.1002/pbc.21618. View